Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Henagliflozin in Type 2 Diabetes Mellitus with Overweight or Obesity (Real-world HbA1c Effect)
ChiCTR2500107605Phase 4Not yet recruiting
- Sponsor
- Beijing Chaoyang Hospital, Capital Medical University
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of henagliflozin in type 2 diabetes mellitus (T2DM), Overweight and obesity, sponsored by Beijing Chaoyang Hospital, Capital Medical University. Primary endpoint: Change in HbA1c from baseline. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
henagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)Overweightobesity
Beyond the preview
Go deeper on ChiCTR2500107605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500107605.